halofuginone has been researched along with Leukemia, Promyelocytic, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assis, PA; Cândido, LA; Chahud, F; De Figueiredo-Pontes, LL; Falcão, RP; Garcia, AB; Leão, V; Lima, AS; Nagler, A; Panepucci, RA; Pintão, CT; Rego, EM; Saggioro, FP | 1 |
| Araújo, AG; Assis, PA; de Figueiredo-Pontes, LL; Falcão, RP; Garcia, AB; Jácomo, RH; Lima, AS; Nagler, A; Panepucci, RA; Rego, EM; Santana-Lemos, BA; Thomé, CH; Zago, MA | 1 |
2 other study(ies) available for halofuginone and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Halofuginone inhibits phosphorylation of SMAD-2 reducing angiogenesis and leukemia burden in an acute promyelocytic leukemia mouse model.
Topics: Animals; Disease Models, Animal; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolinones; Smad2 Protein; Tumor Cells, Cultured | 2015 |
Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway.
Topics: Animals; Blood Cell Count; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Oncogene Proteins, Fusion; Piperidines; Protein Serine-Threonine Kinases; Quinazolinones; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Up-Regulation | 2011 |